Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
- PMID: 30180285
- DOI: 10.1002/hep.30254
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
Abstract
Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease. Our aim was to estimate the total economic burden of NASH and advanced NASH in the United States. We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3). The models comprised patients aged 18+, who moved through seven different health states. We used a lifetime horizon with 1-year cycles for each transition. Cohort size was estimated using US population data, and prevalence and incidence rates were obtained from the literature. Transition probabilities between states were derived from meta-analyses. Costs included inpatient, outpatient, professional services, emergency department, and drug costs, which were obtained from the Center for Medicare and Medicaid Services Fee Schedule 2017 and published data. All future costs were discounted at an annual rate of 3%. Our models estimated that there are 6.65 million adults (18+ years old) with NASH in the United States and that there were 232,000 incident cases in 2017. Lifetime costs of all NASH patients in the United States in 2017 will be $222.6 billion, and the cost of the advanced NASH population will be $95.4 billion. Conclusion: NASH, especially advanced NASH, is associated with high lifetime economic burden; in the absence of treatment, the total direct costs of illness for these patients will continue to grow, and these costs would be even greater if the societal costs are included.
© 2018 by the American Association for the Study of Liver Diseases.
Similar articles
-
Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand.BMC Gastroenterol. 2021 Mar 25;21(1):135. doi: 10.1186/s12876-021-01720-w. BMC Gastroenterol. 2021. PMID: 33765931 Free PMC article.
-
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.Liver Int. 2021 Jun;41(6):1227-1242. doi: 10.1111/liv.14825. Epub 2021 Mar 18. Liver Int. 2021. PMID: 33590598 Free PMC article. Review.
-
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.Diabetes Care. 2020 Feb;43(2):283-289. doi: 10.2337/dc19-1113. Epub 2019 Oct 28. Diabetes Care. 2020. PMID: 31658974
-
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1. Hepatology. 2018. PMID: 28802062 Free PMC article. Review.
-
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26. Hepatology. 2016. PMID: 27543837
Cited by
-
Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment.Heliyon. 2024 Mar 25;10(7):e28468. doi: 10.1016/j.heliyon.2024.e28468. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38689985 Free PMC article. Review.
-
Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule.iScience. 2024 Apr 10;27(5):109688. doi: 10.1016/j.isci.2024.109688. eCollection 2024 May 17. iScience. 2024. PMID: 38660405 Free PMC article.
-
Pegbelfermin for reducing transaminase levels in patients with non-alcoholic steatohepatitis: a dose-response meta-analysis of randomized controlled trials.Front Med (Lausanne). 2024 Apr 5;11:1293336. doi: 10.3389/fmed.2024.1293336. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38646552 Free PMC article.
-
Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients.J Multidiscip Healthc. 2024 Mar 14;17:1127-1135. doi: 10.2147/JMDH.S453429. eCollection 2024. J Multidiscip Healthc. 2024. PMID: 38500481 Free PMC article.
-
Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk.Front Immunol. 2024 Feb 28;15:1337241. doi: 10.3389/fimmu.2024.1337241. eCollection 2024. Front Immunol. 2024. PMID: 38481995 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical